U.S. markets close in 2 hours 36 minutes

AnaptysBio, Inc. (ANAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.59-0.09 (-0.36%)
As of 10:19AM EST. Market open.
Sign in to post a message.
  • p
    Hal Barron, GSK R&D chief

    October 26, 2020 09:20 AM EDT
    Updated 09:37 AM
    With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

    John Carroll
    Editor & Founder

    Hamza Suria
    AnaptysBio $ANAB CEO Hamza Suria is counting up the money he’s due from GlaxoSmithKline.
    GSK’s Hal Barron inherited a partnership with AnaptysBio when he bought out Tesaro and gained the PARP drug Zejula a couple of years ago for $5 billion. And he’s willing to pay for the right to try various checkpoint combination drugs with Zejula now that the PD-1 he also got in the deal is teed up for a likely near-term approval.
    What changed?

    For one, Suria’s company filed a lawsuit against GSK saying they had violated the old Tesaro deal when they started a PD-1 combo study for Zejula using Merck’s PD-1 king Keytruda for non-small cell lung cancer. Their deal, the biotech alleged, was supposed to be exclusive. That lawsuit, scheduled to head to trial next spring, called for GSK to hand back the drug, dubbed dostarlimab. And in August they gave GSK 60 days to cure the breach.
    To facilitate the new deal, GSK is handing over $60 million as an added sweetener in the next month. But they’re also giving AnaptysBio, which licensed out the PD-1 (dostarlimab) to Tesaro 6 years ago — along with TIM-3 (cobolimab) and LAG-3 antibodies (GSK4069889A) — a bigger piece of the checkpoint pie.
    The way the deal was originally structured, AnaptysBio would get a 4%-to-8% slice of the revenue on dostarlimab. That 8% was due on sales over $1 billion a year.
    Now, GSK is willing to pay significantly more in royalties.
    Under the new arrangement, as outlined by Suria’s company, the royalties to AnaptysBio now start at 8% and heads to 25%. That’s 8% for everything below $1 billion and 12% to 25% for everything above the blockbuster line.
    There’s still a little more than a billion dollars in milestones in the deal, and Suria believes he’s going to pick up $75 million in the next 18 months for FDA and EMA approvals of dostarlimab as Barron hunts US approval before the end of the year for endometrial cancer. Not so well known is Barron’s plans to file for using the PD-1 to treat mismatch repair deficient cancers on a pan-tumor basis in H1 2021.
    Suria is counting on $165 million in sales milestones and also gets 1% of all Zejula sales. And the new money is all tied to freeing GSK to do Zejula combos with third-party molecules.
    GSK has had a tough time convincing analysts that the runner-up PARP behind AstraZeneca and the number 7 PD-(L)1 behind a slew of rivals have big futures.
    But he seems absolutely determined to prove them wrong. And he’s willing to pay for the privilege.
    Oncology loomed large when Barron was brought in to head up GSK’s top-15 R&D group. The pharma giant needs to score some significant successes in cancer R&D, following the approval of belantamab mafodotin a few months ago, and they shouldn’t have long to wait now.
  • D
    Top Gainers in the U.S. Stock Markets 🇺🇸

  • A
    MEGA OPP on this Bio Gem below guys :

    ETTX= MC $69 M / Cash $50 M / 2 BIG Phase 3 Drugs with readouts expected next Quarter / Low float Gem / MASSIVE insider & Institutional Ownership = A potential 10++ Bagger

  • N
    This is a classic case that gives us high confidence in success at p-3. GL
  • Y
    Yahoo Finance Insights
    AnaptysBio is up 7.93% to 23.68
  • B
    For a stock that is going up every day this is a very quiet board.
  • Y
    Yahoo Finance Insights
    AnaptysBio is up 7.77% to 21.95
  • Y
    Yahoo Finance Insights
    AnaptysBio is up 8.20% to 27.84
  • Y
    Yahoo Finance Insights
    AnaptysBio is up 8.22% to 26.06
  • T
  • Y
    Yahoo Finance Insights
    AnaptysBio is up 9.80% to 19.50
  • d
    it tanked 70% about a year ago so alot of bagholders are still at a loss from a $70 high..if you bought in about a month ago you are up significantly
  • Y
    Yahoo Finance Insights
    AnaptysBio is up 6.58% to 15.72
  • m
    280,000 shares acquired by Suria Hamza (President, CEO), form 4 filed with the SEC
    280,000 shares acquired by Suria Hamza (President, CEO), form 4 filed with the SEC
  • Y
    I feel like ANAB was oversold today, it could be a good entry point with some obvious risk tied in. If ANAB is able to deliver well on what it has in its pipeline things could be looking on the upside. I still feel like it will have a rebound in the short-term but long-term is more risky but more risk means higher return we will just have to hope that the company is able to deliver and we could see some nice gains and revenues are up $4.8 Million up about 55% year over year so thats also a positive maybe the company will be able to make profits soon if all goes well. But I'll hold out for them and hope for the best
  • L
    Almost all shares seems like owned by institutionals (Nasdaq website).
    I've looked at pipeline, oncoming results of a phase 3 and enough cash.
    (What not to like?)
    I'm thinking to buy some shares.
    Bullish and bearish sentiment appreciated, thx
  • G
    ANAB sunk after news of its failed ATLAS Phase 2b Clinical Trial. ANAB's trades at a considerable 32% discount to its net cash and investments per share of $15.
    ANAB sunk after news of its failed ATLAS Phase 2b Clinical Trial. ANAB's trades at a considerable 32% discount to its net cash and investments per share of $15.
  • R
    Robert K
    This goes down everyday with no apparent news--what gives
  • G
    trading 60% less cash calance + HUGE pipeline = should rebound quickly back to $20 =STRONG BUY its a GIFT
  • J
    Will go to $ 18 soon. From there depending on further results.
    They have huge amounts of cash to finish all trials without printing new shares.
    Let wait and see.